ДЛИТЕЛЬНАЯ АНТИКОАГУЛЯНТНАЯ ТЕРАПИЯ ПРИ ВТОРИЧНОЙ ПРОФИЛАКТИКЕ ОСТРОГО КОРОНАРНОГО СИНДРОМА: КАК ВЫБРАТЬ БОЛЬНОГО?
https://doi.org/10.21518/2307-1109-2016-1-26-38
Аннотация
Обзор посвящен актуальным вопросам антитромботической терапии больных, перенесших острый коронарный синдром. Обсуждаются эффективность и безопасность длительного назначения антикоагулянтов (как варфарина, так и новых антикоагулянтов) в дополнение к стандартному антитромбоцитарному лечению. Особое внимание уделяется ривароксабану, показания к назначению низкой дозы которого зарегистрированы для профилактики сосудистой смерти и инфаркта миокарда у пациентов после острого коронарного синдрома, протекавшего с повышением маркеров повреждения миокарда. Обсуждаются клинические характеристики больных, подходящих для такого лечения.
Об авторе
А. Л. Комаров
Институт клинической кардиологии им. А. Л. Мясникова Российского кардиологического научно-производственного комплекса, Москва
Россия
Доктор медицинских наук
Россия
Доктор медицинских наук
Список литературы
1. Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST ЭКГ. Рекомендации ВНОК. Ред. Руда М.Я. Кардиоваскулярная терапия и профилактика, Приложение 1, 2007, 6(8): 415-500.
2. Национальные рекомендации по антитромботической терапии у больных со стабильными проявлениями атеротромбоза. Кардиоваскулярная терапия и профилактика, Приложение 6, 2009, 8(6).
3. 2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, doi:10.1093/eurheartj/ehu278.
4. 2013 ACCF/AHA Guideline for the Management of STElevation Myocardial Infarction. JACC, 2013, 61(4): e78140.
5. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2014, 64(Issue 24): e139-e228.
6. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33: 2569-2619. doi:10.1093/eurheartj/ehs215.
7. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37: 267-315. doi:10.1093/eurheartj/ehv320.
8. Fuster V, Moreno PR, Fayad ZA et al. Atherothrombosis and High-Risk Plaque. J Am Coll Cardiol, 2005, 46: 93754.
9. Fuster V, Badimon JJ, Chesebro JH. Atherothrombosis: mechanisms and clinical therapeutic approaches. Vascular Medicine, 1998, 3: 231-239.
10. Falk E. Pathogenesis of Atherosclerosis. J Am Coll Cardiol, 2006, 47: C7-12.
11. Rodriguez T, Malvezzi M, Chatenoud L, Bosetti C, Levi F, Negri E et al. Trends in mortality from coronary heart and cerebrovascular diseases in the Americas: 19702000. Heart, 2006, 92(4): 453-460.
12. Tricoci P, Huang Z, Held C et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med, 2012, 366: 20-33.
13. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med, 1988, 319: 1105-11.
14. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet, 1990, 336: 827-30.
15. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina a metaanalysis. JAMA, 1996, 276: 811-5.
16. Stone GW, Maehara A, Lansky AJ et al. A prospective naturalhistory study of coronary atherosclerosis. N Engl J Med, 2011, 364: 226-235.
17. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acure coronary syndromes. N Engl J Med, 2009, 361(11): 1045-1057.
18. Morange PE, Bickel C, Nicaud V et al. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arterioscler Thromb Vasc Biol, 2006, 26: 2793-2799.
19. Merlini PA, Bauer KA, Oltrona L, Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation, 1994, 90: 61-68.
20. Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. , 2001, 21(4): 611-617.
21. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation, 2005, 112(20): 3080-3087.
22. Morange PE, Bickel C, Nicaud V, Schnabel R, Rupprecht HJ, Peetz D, Lackner KJ, Cambien F, Blankenberg S, Tiret L. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arterioscler Thromb Vasc Biol, 2006, 26(12): 2793-2799.
23. Komarov A, Panchenko E, Dobrovolsky A, et al. D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease. Eur Heart J, 2002 Aug, 23(16): 1309-16.
24. Husted SE, Wallentin L, Lagerqvist B, Kontny F, Stahle E, Swahn E.Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. European Heart Journal, 2002, 23: 1213-1218.
25. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med, 2002, 347: 969-74.
26. Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: An updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J, 2006, 27: 519-526.
27. Wallentin L, Wilcox RG, Weaver WD et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: The ESTEEM randomised controlled trial. Lancet, 2003, 362: 789-797.
28. AstraZeneca. AstraZeneca decides to withdraw ExantaTM. 2006. Available at: http://www.astrazeneca.com/Media/Pressreleases/Article/ 20060214—AstraZeneca-Decides-toWithdraw-Exanta (Accessed 19 June 2014).
29. Hansen M L, So/rensen R, Clausen M T et al. Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation. Arch Intern Med, 2010, 170(16): 1433-1441.
30. So/rensen R, Hansen M L, Abildstrom S Z, et al. Risk of bleeding in patients with acute myocardial infarction treated with diff erent combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet, 2009, 374: 1967-74.
31. Lamberts M, Gislason G H, Olesen J B, et al. Oral Anticoagulation and Antiplatelets in Atrial Fibrillation Patients After Myocardial Infarction and Coronary Intervention. J Am Coll Cardiol, 2013, 62: 981-9.
32. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: A randomized, double-blind, phase II trial. Eur Heart J, 2011, 32: 2781-2789.
33. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med, 2011, 365: 699-708.
34. Mega L, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, doubleblind, phase II trial. Lancet, 2009, 374: 29-38. 3
35. Jessica L Mega, Eugene Braunwald, Stephen D Wiviott et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med, 2012, 366: 9-19.
36. Gibson C.M, Chakrabarti A K., Mega J, et al. Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol, 2013, 62: 286-90.
37. Mega J L, Braunwald E, Murphy S A., et al. Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol, 2013, 61: 18539.
38. Mega JL, Braunwald E, Murphy SA et al. Rivaroxaban in patients after an acute coronary syndrome with cardiac biomarker elevation (with or without prior stroke or TIA): insights from the ATLAS ACS 2 TIMI 51 trial, P5518, ESC CONGRESS 2014.
39. Stachon P, Ahrens I, Bode C, Zirlik A. Dual pathway therapy in acute coronary syndrome. J Thromb Thrombolysis. DOI 10.1007/s11239-015-1306-3.
40. http://www.crusadebleedingscore.org.
41. Аверков О.В., Комаров А.Л., Панченко Е.П., Руда М.Я., Сыркин А.Л., Шахнович Р.М., Явелов И.С. Резюме совета экспертов, посвященного обсуждению значения препарата ривароксабан в лечении больных, переживших острый коронарный синдром. Неотложная кардиология, 2015, 3: 38-44.
42. Xarelto Assessment report EMA/342289/2013. www.ema.europa.eu.
43. Karve AM, Seth M, Sharma M. Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). Am J Cardiol, 2015 Jun 1, 115(11): 1502-6. doi: 10.1016/j.amjcard.2015.02.049.
44. Damman P, Varenhorst C, Koul S et al. Treatment Patterns and Outcomes in Patients Undergoing Percutaneous Coronary Intervention Treated With Prasugrel or Clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]). Am J Cardiol, 2014, 113: 64e69.
45. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study. http://acc.sagepub.com/content/early/2014/11/20/204 8872614560505.
46. Gandhi S, Zile B, Tan MK. Increased Uptake of Guideline Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective. Canadian Journal of Cardiology, 2014. doi: 10.1016/j.cjca.2014.09.011.
47. Эрлих А.Д., Мацкеплишвили С.Т., Грацианскии, Н.А., Бузиашвили Ю.И. и все участники Московского регистра ОКС. Первый Московский регистр острого коронарного синдрома: характеристика больных, лечение и исходы за время пребывания в стационаре. Кардиология, 2013, 12: 4-13.
48. Boles U, Rakhit R, Shiu M F, Patel K, Henein M. Coronary artery ectasia as a culprit for acute myocardial infarction: review of pathophysiology and management. Anadolu Kardiyol Derg, 2013, 13: 695-701.
Рецензия
Для цитирования:
Комаров А.Л. ДЛИТЕЛЬНАЯ АНТИКОАГУЛЯНТНАЯ ТЕРАПИЯ ПРИ ВТОРИЧНОЙ ПРОФИЛАКТИКЕ ОСТРОГО КОРОНАРНОГО СИНДРОМА: КАК ВЫБРАТЬ БОЛЬНОГО? Атеротромбоз. 2016;(1):26-38. https://doi.org/10.21518/2307-1109-2016-1-26-38
For citation:
Komarov A.L. LONG-TERM ANTICOAGULATION THERAPY IN SECONDARY PREVENTION OF ACUTE CORONARY SYNDROME: HOW TO CHOOSE THE PATIENT? Aterotromboz = Atherothrombosis. 2016;(1):26-38. (In Russ.) https://doi.org/10.21518/2307-1109-2016-1-26-38
Просмотров:
1830
Контент доступен под лицензией Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Послать статью по эл. почте 